Prevention and treatment of human metabolic syndrome including type 2 diabetes, steatohepatitis and related conditions using non-absorbable, orally administered compounds
WO2005099687A2
Analogs of salinosporamide a
US3974183A
Reduction of trans-1-(2-carboxymethyl-3-hydroxy-5-p-phenylbenzoyloxycyclopentyl)-1-octen-3-one-γ-lactone
US3867460A
Reagents for the stereoselective generation of the chiral sidechain carbinol unit (C-15) in prostaglandin synthesis
